secwatch.observer — SEC 8-K summary
======================================

Issuer:     IDEXX LABORATORIES INC /DE (IDXX)
CIK:        0000874716
Form:       8-K
Filed at:   2026-01-13T23:59:59+00:00
Accession:  0001104659-26-003103
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IDEXX CEO succession: Mike Erickson to become President and CEO on May 12, 2026; Mazelsky to Executive Chair
--------------------------------------------------------------------------------

- Jay Mazelsky steps down as CEO effective May 12, 2026, transitions to Executive Chair; will retire from board in May 2027.
- Michael Erickson, PhD (EVP & GM Global Point of Care), promoted to President and CEO, joining the board.
- Erickson's compensation: $1M base salary, 120% target bonus, FY2026 equity target at least $7.8M (50% options, 50% PSUs).
- Mazelsky's Executive Chair compensation: $1.15M base, blended bonus target, $8.275M RSU grant in Feb 2026.
- Lawrence Kingsley, currently Non-Executive Chair, becomes independent Lead Director after transition.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/874716/000110465926003103/0001104659-26-003103-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/874716/000110465926003103/tm262817d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-003103

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer